Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PID23 in Relapsed/Refractory Acute Leukemia
NCT07696481Phase 1Not yet recruiting
- Sponsor
- Southern Medical University Zhujiang Hospital
- Start
- Aug 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PID23 in acute leukemia, sponsored by Southern Medical University Zhujiang Hospital. Primary endpoints: Incidence of Dose-Limiting Toxicities at 21 days and Incidence and Severity of Treatment-Emergent Adverse Events at 2 years. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
PID23
03
Conditions
acute leukemia
Beyond the preview
Go deeper on NCT07696481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07696481.